Korro Bio Statistics
Total Valuation
Korro Bio has a market cap or net worth of $194.08 million. The enterprise value is $98.38 million.
| Market Cap | 194.08M |
| Enterprise Value | 98.38M |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Korro Bio has 14.73 million shares outstanding. The number of shares has increased by 28.33% in one year.
| Current Share Class | 14.73M |
| Shares Outstanding | 14.73M |
| Shares Change (YoY) | +28.33% |
| Shares Change (QoQ) | +51.90% |
| Owned by Insiders (%) | 0.98% |
| Owned by Institutions (%) | 69.50% |
| Float | 10.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 83.24 |
| Forward PS | 279.92 |
| PB Ratio | 1.85 |
| P/TBV Ratio | 1.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 43.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.55, with a Debt / Equity ratio of 0.41.
| Current Ratio | 9.55 |
| Quick Ratio | 9.11 |
| Debt / Equity | 0.41 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -89.63 |
Financial Efficiency
Return on equity (ROE) is -97.69% and return on invested capital (ROIC) is -31.50%.
| Return on Equity (ROE) | -97.69% |
| Return on Assets (ROA) | -27.95% |
| Return on Invested Capital (ROIC) | -31.50% |
| Return on Capital Employed (ROCE) | -50.99% |
| Weighted Average Cost of Capital (WACC) | 13.81% |
| Revenue Per Employee | $41,789 |
| Profits Per Employee | -$1.87M |
| Employee Count | 57 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Korro Bio has paid $839,000 in taxes.
| Income Tax | 839,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.55% in the last 52 weeks. The beta is 2.21, so Korro Bio's price volatility has been higher than the market average.
| Beta (5Y) | 2.21 |
| 52-Week Price Change | -31.55% |
| 50-Day Moving Average | 12.54 |
| 200-Day Moving Average | 11.85 |
| Relative Strength Index (RSI) | 55.76 |
| Average Volume (20 Days) | 105,882 |
Short Selling Information
The latest short interest is 1.44 million, so 9.77% of the outstanding shares have been sold short.
| Short Interest | 1.44M |
| Short Previous Month | 1.46M |
| Short % of Shares Out | 9.77% |
| Short % of Float | 13.74% |
| Short Ratio (days to cover) | 7.58 |
Income Statement
In the last 12 months, Korro Bio had revenue of $2.38 million and -$106.64 million in losses. Loss per share was -$8.88.
| Revenue | 2.38M |
| Gross Profit | -41.02M |
| Operating Income | -76.90M |
| Pretax Income | -105.81M |
| Net Income | -106.64M |
| EBITDA | -74.33M |
| EBIT | -76.90M |
| Loss Per Share | -$8.88 |
Balance Sheet
The company has $115.04 million in cash and $42.21 million in debt, with a net cash position of $95.71 million or $6.50 per share.
| Cash & Cash Equivalents | 115.04M |
| Total Debt | 42.21M |
| Net Cash | 95.71M |
| Net Cash Per Share | $6.50 |
| Equity (Book Value) | 103.23M |
| Book Value Per Share | 7.02 |
| Working Capital | 108.00M |
Cash Flow
In the last 12 months, operating cash flow was -$67.95 million and capital expenditures -$317,000, giving a free cash flow of -$68.27 million.
| Operating Cash Flow | -67.95M |
| Capital Expenditures | -317,000 |
| Depreciation & Amortization | 2.57M |
| Net Borrowing | n/a |
| Free Cash Flow | -68.27M |
| FCF Per Share | -$4.64 |
Margins
| Gross Margin | n/a |
| Operating Margin | -3,228.34% |
| Pretax Margin | -4,441.86% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Korro Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -28.33% |
| Shareholder Yield | -28.33% |
| Earnings Yield | -53.78% |
| FCF Yield | -34.43% |
Analyst Forecast
The average price target for Korro Bio is $20.20, which is 53.26% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.20 |
| Price Target Difference | 53.26% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Korro Bio has an Altman Z-Score of -2.55 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.55 |
| Piotroski F-Score | 2 |